CSF1R and neoplasm: Both subtypes share the potential to benefit from CSF-1R inhibitors and other strategies aimed at repolarizing TAMs to the M1 phenotype, which could shift the tumor from cold to hot, enhancing the effectiveness of immunotherapies [46, 47].